Clinical trial recruitment challenges with older adults with cancer

Payne, Jason; Hendrix, Cristina C.

doi:10.1016/j.apnr.2008.12.004

Cited by 18 publications

(14 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Within studies of cancer survivors, population-based data (such as that collected by cancer registries) should consider inclusion of comorbidity as a standard data element (20). More cancer clinical trials are needed that include adults age 65 and older, many of whom may have pre-existing health conditions and functional limitations, and are often excluded from cancer-related research studies and therapeutic trials specifically (28). These will require trial designs that include and thoughtfully consider the effects of concurrent health conditions, rather than exclude them (29, 30).…”

Section: Discussionmentioning

confidence: 99%

Cancer Survivors: A Booming Population

Parry

Kent

Mariotto

et al. 2011

Cancer Epidemiology, Biomarkers &Amp; Prevention

390

268

View full text Add to dashboard Cite

Background In this first article of what is planned to be an annual series, we examine the history of cancer prevalence reporting and the role that these annual figures play in guiding the direction of cancer control research, and specifically the science of cancer survivorship. For this inaugural year, we focus on the confluence of the growing number of survivors and population aging, and the impact these combined trends will have on cancer survivorship in the future. Methods State or metro area-level cancer incidence and prevalence data were collected from 9 registries via the Surveillance, Epidemiology, and End Results (SEER) Program. The complete prevalence method was used to estimate prevalence for 2008 and the Prevalence, Incidence Approach MODel (PIAMOD) method was used to project prevalence data through 2020, assuming flat cancer incidence and survival trends but dynamic U.S. population projections. Results As of January 2008, the number of cancer survivors is estimated at 11.9 million. Approximately 60% of cancer survivors are age 65 or older, and by the year 2020, it is estimated that 63% of cancer survivors will be age 65 or older. Conclusions Improved survival and population aging converge to generate a booming population of older adult cancer survivors, many of whom have multiple complex health conditions and unique survivorship needs. This demographic shift has important implications for future healthcare needs and costs of the United States population. Impact The findings provide information critical for guiding cancer prevention and control research and service provision.

show abstract

Section: Discussionmentioning

confidence: 99%

Cancer Survivors: A Booming Population

Parry

Kent

Mariotto

et al. 2011

Cancer Epidemiology, Biomarkers &Amp; Prevention

390

268

View full text Add to dashboard Cite

show abstract

“…In order to tackle continuing health disparities, research and public research participation must include racial/ethnic minority groups who are often disproportionately affected by diseases such as stroke, heart disease, and HIV/AIDS . Since 1993, the NIH has called for more balanced representation of the nation's population in clinical trials, and a large body of subsequent literature has identified attitudes, barriers, facilitators, and methods to increase specific populations’ participation in clinical research . However, existing evidence about public participation in research commonly focuses on disease‐specific and/or minority group patterns, rather than taking a national perspective.…”

Section: Introductionmentioning

confidence: 99%

“…4 Since 1993, the NIH has called for more balanced representation of the nation's population in clinical trials, 5 and a large body of subsequent literature has identified attitudes, barriers, facilitators, and methods to increase specific populations' participation in clinical research. [6][7][8][9][10][11][12][13][14] However, existing evidence about public participation in research commonly focuses on disease-specific and/or minority group patterns, [15][16][17][18][19] rather than taking a national perspective.…”

Section: Introductionmentioning

confidence: 99%

Public Interest in Medical Research Participation: Differences by Volunteer Status and Study Type

Cobb

Singer

Davis

2014

Clinical Translational Sci

View full text Add to dashboard Cite

Purpose We assessed national levels of public interest in medical research participation (MRP) and factors associated with interest as a healthy volunteer; as a diagnosed volunteer; and in seven study types. Method Cross-sectional, web-based survey of the US population in June 2012. Descriptive statistics estimated interest in MRP and multivariable logistic regression determined associations between respondent-level predictors and interest in MRP. Results Of 2,668 respondents (response rate=61%), 41% were interested in MRP as healthy volunteers and 60% as diagnosed volunteers. Respondents with some college (OR=1.54, 1.09–2.19) or higher education (OR=1.86, 1.29–2.70) had higher adjusted odds of interest as healthy volunteers. Non-Hispanic black race (OR=0.56, 0.37–0.86) and education below high school (OR=0.57, 0.35–0.92) were associated with lower adjusted odds of interest as diagnosed volunteers. Non-Hispanic black race was associated with lower odds of interest in medication trials as diagnosed volunteers (OR=0.61, 0.40–0.93). Conclusions We found high levels of interest in MRP that contrast with low levels of prior research participation. Interest is higher in medical research involving noninvasive designs. Comparatively lower levels of interest in MRP among non-Hispanic blacks and those with less education raise concerns about disparities in future study enrollment.

show abstract

“…Flexibility and adapting to recruitment issues that arise are the keys to success (McCormick et al, 1999). Barriers to successful recruitment can involve patients, providers, and system level issues (Payne & Hendrix, 2010). For instance, patients do not always know enough about research and thus need information for informed choices about participation, particularly when a trial is lengthy, when physical limitations make participation difficult (Ackerman, Buchbinder, & Osborne, 2012) or when the intervention assignment is favored by patients (Jones & Reiner, 2010).…”

Section: Introductionmentioning

confidence: 99%

“…With knowledge of these issues and careful planning, even these can be overcome. For example, in a study recruiting adults with cancer, adaptations were made so that the data collection and intervention components could be conducted in the study participants’ homes since mobility was an issue for many in this patient population (Payne & Hendrix, 2010). …”

Section: Introductionmentioning

confidence: 99%

Successful recruitment methods in the community for a two-site clinical trial

Fairbanks

Shah

Wilde

et al. 2014

Applied Nursing Research

View full text Add to dashboard Cite

Effective screening and recruitment are essential to the success of randomized clinical trials. This report is to describe key screening and recruitment strategies in a two site randomized clinical trial (RCT) conducted in community settings with a vulnerable chronically ill population and to suggest valuable approaches when planning trials. Differences between sites in a complex study with two considerably different environments (academic versus home care) and their participant pools presented challenges which required different screening and recruitment methods. A high level of communication between sites, creative problem solving and the ability to be flexible when problems were encountered were needed for successful screening and recruitment.

show abstract

Clinical trial recruitment challenges with older adults with cancer

Cited by 18 publications

References 9 publications

Cancer Survivors: A Booming Population

Cancer Survivors: A Booming Population

Public Interest in Medical Research Participation: Differences by Volunteer Status and Study Type

Successful recruitment methods in the community for a two-site clinical trial

Contact Info

Product

Resources

About